Consistently, our data demonstrated that the combination treatment of Nrf2 inhibitor or Ibrutinib with RSL3 or Erastin had a synergistic effect on inhibition of CRC cell proliferation, viability as well as antioxidant proteins. The gene discussed is NFE2L2; the disease is colorectal carcinoma.